Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fudan University | OTHER |
| First Affiliated Hospital of Harbin Medical University | OTHER |
| First Affiliated Hospital Xi'an Jiaotong University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The pathogenesis of dilated cardiomyopathy (DCM) leading to heart failure is closely associated with autoimmunity dysfunction. A few studies represented that Qiliqiangxin capsule, a Chinese medicine, could enhance heart function in chronic heart failure and regulate the balance of TNF-a and IL-10 in myocardial infarction. In this study, to explore the effects of Qiliqiangxin capsule on the improving heart function and immunoregulation in patients with DCM, patients were recruited, anti-heart autoantibodies and some representative cytokines were assayed by enzyme-linked immuno sorbent assay (ELISA), and the efficacy of heart function improvement was compared between Qiliqiangxin capsule and placebo under the standard treatment of DCM.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Qiliqiangxin capsule | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Qiliqiangxin capsule | Drug | Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period. |
| Measure | Description | Time Frame |
|---|---|---|
| The value of left ventricular end-diastolic dimension (LVEDd) and left ventricular ejection fraction(LVEF) confirmed by ultrasonic cardiogram (UCG) | 12 months after intervention | |
| The levels of serum representative cytokines detected by ELISA | 12 months after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Heart failure aggravation | 12 months after intervention | |
| All cause mortality | 12 months after intervention | |
| Sudden cardiac death |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yu-Hua Liao, Docter | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | 430022 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20448127 | Background | Tang H, Zhong Y, Zhu Y, Zhao F, Cui X, Wang Z. Low responder T cell susceptibility to the suppressive function of regulatory T cells in patients with dilated cardiomyopathy. Heart. 2010 May;96(10):765-71. doi: 10.1136/hrt.2009.184945. | |
| 20802148 | Background | Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010 Oct 1;185(7):4004-10. doi: 10.4049/jimmunol.1001718. Epub 2010 Aug 27. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002311 | Cardiomyopathy, Dilated |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006332 | Cardiomegaly |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D009202 | Cardiomyopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| C572413 | qiliqiangxin |
Not provided
Not provided
Not provided
| Shandong Provincial Hospital |
| OTHER_GOV |
| The First Affiliated Hospital with Nanjing Medical University | OTHER |
| First Affiliated Hospital of Guangxi Medical University | OTHER |
| The First Affiliated Hospital of Zhengzhou University | OTHER |
| Ministry of Science and Technology of the PeopleĀ“s Republic of China | OTHER_GOV |
| China National Center for Cardiovascular Diseases | OTHER_GOV |
| RenJi Hospital | OTHER |
| Second Affiliated Hospital of Xi'an Jiaotong University | OTHER |
| The Second Affiliated Hospital of Harbin Medical University | OTHER |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | OTHER |
| Tongji Hospital | OTHER |
| Wuhan University | OTHER |
| Henan Provincial People's Hospital | OTHER |
| Jining Medical University | OTHER |
| Second Hospital of Shanxi Medical University | OTHER |
| Shanxi Cardiovascular Hospital | OTHER |
| Wuhan Pu-Ai Hospital | OTHER |
| Tianyou Hospital Affiliated to Wuhan University of Science and Technology | OTHER |
| Yunyang Medical College | OTHER |
| China Three Gorges University, Yichang, China | OTHER |
| Xiangyang Central Hospital | OTHER |
| Wuhan No.1 Hospital | OTHER |
| Jingzhou Central Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period. |
|
| 12 months after intervention |
| Stroke | 12 months after intervention |
| The dynamic changes of serum representative cytokines detected by ELISA in the treatment group | 12 months after intervention |
| 21044990 | Background | Xiao H, Wang M, Du Y, Yuan J, Cheng X, Chen Z, Zou A, Wei F, Zhao G, Liao YH. Arrhythmogenic autoantibodies against calcium channel lead to sudden death in idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar;13(3):264-70. doi: 10.1093/eurjhf/hfq198. Epub 2010 Nov 2. |
| 19833326 | Background | Xiao H, Song Y, Li Y, Liao YH, Chen J. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol. 2009;260(1):51-5. doi: 10.1016/j.cellimm.2009.09.001. Epub 2009 Sep 11. |
| D000083083 |
| Laminopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |